Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24 | Morningstar

[GlobeNewswire](/news/globe-newswire) Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24 - High CEACAM1 and low PDL1 expression in tumors, as well as t
Read more...